The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor - PubMed (original) (raw)
. 2004 Aug;18(8):2011-23.
doi: 10.1210/me.2004-0065. Epub 2004 May 6.
Affiliations
- PMID: 15131260
- DOI: 10.1210/me.2004-0065
The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor
Mark Powzaniuk et al. Mol Endocrinol. 2004 Aug.
Abstract
The androgen receptor (AR) is a member of the steroid receptor superfamily that plays critical roles in the development and maintenance of the male reproductive system and in prostate cancer. Actions of AR are controlled by interaction with several classes of coregulators. In this study, we have identified LATS2/KPM as a novel AR-interacting protein. Human LATS1 and LATS2 are tumor suppressors that are homologs of Drosophila warts/lats. The interaction surface of LATS2 is mapped to the central region of the protein, whereas the AR ligand binding domain is sufficient for this interaction. LATS2 functions as a modulator of AR by inhibiting androgen-regulated gene expression. The mechanism of LATS2-mediated repression of AR activity appears to involve the inhibition of AR NH2- and COOH-terminal interaction. Chromatin immunoprecipitation assays in human prostate carcinoma cells reveal that LATS2 and AR are present in the protein complex that binds at the promoter and enhancer regions of prostate-specific antigen, and overexpression of LATS2 results in a reduction in androgen-induced expression of endogenous prostate-specific antigen mRNA. Immunohistochemistry shows that LATS2 and AR are localized within the prostate epithelium and that LATS2 expression is lower in human prostate tumor samples than in normal prostate. The results suggest that LATS2 may play a role in AR-mediated transcription and contribute to the development of prostate cancer.
Similar articles
- Negative modulation of androgen receptor transcriptional activity by Daxx.
Lin DY, Fang HI, Ma AH, Huang YS, Pu YS, Jenster G, Kung HJ, Shih HM. Lin DY, et al. Mol Cell Biol. 2004 Dec;24(24):10529-41. doi: 10.1128/MCB.24.24.10529-10541.2004. Mol Cell Biol. 2004. PMID: 15572661 Free PMC article. - The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes.
Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, Wang Y, Jin R, Gupta A, Rennie PS, Matusik RJ. Gao N, et al. Mol Endocrinol. 2003 Aug;17(8):1484-507. doi: 10.1210/me.2003-0020. Epub 2003 May 15. Mol Endocrinol. 2003. PMID: 12750453 - Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.
Sampson ER, Yeh SY, Chang HC, Tsai MY, Wang X, Ting HJ, Chang C. Sampson ER, et al. J Biol Regul Homeost Agents. 2001 Apr-Jun;15(2):123-9. J Biol Regul Homeost Agents. 2001. PMID: 11501969 Review. - Molecular communication between androgen receptor and general transcription machinery.
Lee DK, Chang C. Lee DK, et al. J Steroid Biochem Mol Biol. 2003 Jan;84(1):41-9. doi: 10.1016/s0960-0760(03)00005-0. J Steroid Biochem Mol Biol. 2003. PMID: 12648523 Review.
Cited by
- Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase.
Ma B, Chen Y, Chen L, Cheng H, Mu C, Li J, Gao R, Zhou C, Cao L, Liu J, Zhu Y, Chen Q, Wu S. Ma B, et al. Nat Cell Biol. 2015 Jan;17(1):95-103. doi: 10.1038/ncb3073. Epub 2014 Dec 1. Nat Cell Biol. 2015. PMID: 25438054 - FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment.
Ma Q, Fu W, Li P, Nicosia SV, Jenster G, Zhang X, Bai W. Ma Q, et al. Mol Endocrinol. 2009 Feb;23(2):213-25. doi: 10.1210/me.2008-0147. Epub 2008 Dec 12. Mol Endocrinol. 2009. PMID: 19074551 Free PMC article. - The Hippo pathway: an emerging role in urologic cancers.
Cinar B, Alp E, Al-Mathkour M, Boston A, Dwead A, Khazaw K, Gregory A. Cinar B, et al. Am J Clin Exp Urol. 2021 Aug 25;9(4):301-317. eCollection 2021. Am J Clin Exp Urol. 2021. PMID: 34541029 Free PMC article. Review. - Interplay of Developmental Hippo-Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer.
Mourkioti I, Angelopoulou A, Belogiannis K, Lagopati N, Potamianos S, Kyrodimos E, Gorgoulis V, Papaspyropoulos A. Mourkioti I, et al. Cells. 2022 Aug 7;11(15):2449. doi: 10.3390/cells11152449. Cells. 2022. PMID: 35954292 Free PMC article. Review. - Clinicopathological Significance of Large Tumor Suppressor (LATS) Expression in Gastric Cancer.
Son MW, Song GJ, Jang SH, Hong SA, Oh MH, Lee JH, Baek MJ, Lee MS. Son MW, et al. J Gastric Cancer. 2017 Dec;17(4):363-373. doi: 10.5230/jgc.2017.17.e41. Epub 2017 Dec 26. J Gastric Cancer. 2017. PMID: 29302376 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials